Welcome to our dedicated page for STEPAN CO SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
Stepan Company reported a sharp swing to a loss in Q1 2026, driven by a major restructuring under Project Catalyst. Net sales rose slightly to $604.5 million, but the company recorded a net loss of $41.4 million, or $(1.81) per diluted share, versus earnings of $0.86 a year earlier.
The loss reflects a $65.4 million pre-tax business restructuring charge tied to shutting down the Fieldsboro, New Jersey site and decommissioning assets at the Millsdale, Illinois and Stalybridge, U.K. facilities. Adjusted net income was $10.3 million, or $0.45 per diluted share, down from $0.84.
Surfactants remained the largest segment, generating $453.7 million of net sales but lower operating income, while Polymers earned slightly more despite an 11% sales decline. Specialty Products grew sales 24% but saw lower profit due to product mix and higher raw material costs. Operating cash flow improved to $16.9 million, and Stepan ended the quarter with $140.8 million in cash and $651.7 million of total debt.
Stepan Company executive Robert Joseph Haire reported routine equity compensation activity involving restricted stock units (RSUs). On May 1, 2026, 550 RSUs were settled into the same number of common shares, consistent with the award terms that each RSU converts into one share.
To cover associated tax liabilities on the RSU vesting, 162 common shares were withheld, a non‑market disposition that does not represent an open‑market sale. After these transactions, Haire directly holds approximately 3,959.765 shares of Stepan common stock.
Stepan Company reported voting results from its April 28, 2026 annual stockholder meeting. A quorum was present, with 19,939,848 common shares represented in person or by proxy.
Stockholders elected three directors to terms expiring in 2029. Joaquin Delgado received 17,708,824 votes for and 574,142 against, Corning F. Painter received 18,083,634 for and 199,377 against, and F. Quinn Stepan, Jr. received 17,761,172 for and 528,911 against, with additional abstentions and broker non-votes on each nominee.
Stockholders approved, on an advisory basis, the compensation of Stepan’s named executive officers, with 17,000,565 votes for, 1,233,415 against, and 67,131 abstentions. They also ratified the appointment of Deloitte & Touche LLP as Stepan’s independent registered public accounting firm for 2026, with 19,630,780 votes for, 289,370 against, and 19,698 abstentions.
Vanguard Portfolio Management reports beneficial ownership of 1,372,514 shares of Stepan Co common stock, representing 6.04% of the class as reported in a Schedule 13G. The filing shows sole voting power 13,661 and sole dispositive power 1,372,514, with the position tied to Vanguard-managed funds and accounts.
Stepan Company reported a first quarter 2026 net loss of $41.4 million, or $(1.81) per diluted share, compared with net income of $19.7 million a year earlier. The loss was driven by a previously announced pre-tax business restructuring charge of $65.4 million related to closing the Fieldsboro, NJ site and decommissioning select assets in Illinois and the UK.
Excluding deferred compensation, environmental items and restructuring, adjusted net income was $10.3 million, down 47%, and adjusted earnings per diluted share were $0.45 versus $0.84. Net sales rose 2% to $604.5 million, while consolidated adjusted EBITDA fell 14% to $49.6 million as weaker Surfactants performance outweighed stronger Polymers results.
Surfactants net sales increased 5% to $453.7 million, but adjusted EBITDA declined 15%. Polymers net sales declined 11% to $130.0 million, while adjusted EBITDA grew 8% on margin improvement. Specialty Products net sales rose 24% to $20.8 million, with adjusted EBITDA down 11%. Stepan generated operating cash flow of $16.9 million and negative free cash flow of $14.0 million after $30.9 million of capital expenditures.
The company also entered into an agreement to sell a parcel of land near its Millsdale site for $30 million, subject to customary closing conditions. Separately, the Board declared a quarterly cash dividend of $0.395 per share, payable on June 15, 2026 to shareholders of record on June 1, 2026.
Stepan Co vice president Robin Joseph Weitkamp received new equity awards as part of compensation. On April 13, 2026, he was granted 2,859 restricted stock units, each representing a contingent right to one share of Stepan common stock, vesting ratably over three years.
He also received 4,030 stock appreciation rights on Stepan common stock at an exercise price of $52.46 per share, exercisable beginning April 13, 2027 and expiring April 13, 2036. In addition, he was granted 1,429 performance shares, each a contingent right to one share that vests only if Stepan certifies that performance goals are achieved for the period ending December 31, 2028. These awards are grants, not open‑market purchases or sales.
Stepan Company VP and GM Surfactants NA Afonso Adriano Jose Galimberti received new equity-based awards as part of his compensation. On April 13, 2026, he was granted 1,310 performance shares, 2,621 restricted stock units, and 3,694 stock appreciation rights with a $52.46 exercise price. The performance shares vest if Stepan meets performance goals for the period ending December 31, 2028. The restricted stock units vest ratably over three years beginning on the grant date.
STEPAN CO executive Afonso Adriano Jose Galimberti, VP and GM Surfactants NA, filed an initial ownership report showing equity awards and share holdings. He holds stock options and stock appreciation rights over several thousand shares of common stock at exercise prices between $50.06 and $123.73, plus restricted stock units, performance shares, and direct and indirect common stock, including shares held through an ESOP II trust.
Stepan Company executive Robin Joseph Weitkamp, VP and GM Surfactants-INT, filed an initial ownership report showing various equity-based awards. The filing lists restricted stock units, stock appreciation rights and performance shares that each represent contingent rights to receive Stepan common stock, subject to time-based vesting and performance goals. It also notes an indirect holding of 96.9 shares of common stock through an ESOP II Trust.
Stepan Co ownership filing: The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting that, after an internal realignment effective January 12, 2026, Vanguard and its disaggregated subsidiaries hold 0 shares of Stepan Co common stock, representing 0% of the class. The filing states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries and confirms the reporting group’s voting and dispositive powers are all 0. The form is signed by the Head of Global Fund Administration on 03/27/2026.